Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

First Line Durvalumab in Patients With PD-L1 Positive, Advanced NSCLC With Performance Status 2 Unsuitable for Combination Chemotherapy. A Multicenter, Single-arm Phase II Trial

NCT03620669 is registered in ClinicalTrials.gov with Swiss Cancer Institute as lead sponsor.

NCT NCT03620669
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03620669 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
First Line Durvalumab in Patients With PD-L1 Positive, Advanced NSCLC With Performance Status 2 Unsuitable for Combination Chemotherapy. A Multicenter, Single-arm Phase II Trial
Lead sponsor
Swiss Cancer Institute
Phase
Phase 2
Overall status
Active, not recruiting
Start date
December 4, 2018
Completion date
September 30, 2027
Enrollment
48 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

nsclc stage iiib, nsclc stage iv